You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.
The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.
A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
Recently presented data confirm prior findings that Agendia's MammaPrint may help doctors decide whether to limit tamoxifen treatment in certain patients.
Epic may also develop a liquid biopsy test combining the chromosomal instability biomarker with other markers to predict prostate cancer treatment response.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.